Bristol Myers exits its Cellares CAR-T manufacturing deal after the Cell Shuttle falls short, prompting a reorg at Cellares.
After a “comprehensive evaluation,” Bristol Myers Squibb has pulled out of its partnership with Cellares and the cell therapy manufacturer will restructure as a result.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Cellares cuts 100 jobs after Bristol Myers ends Breyanzi manufacturing deal; startup disputes claims its Cell Shuttle tech fell…
The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO…
With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough…
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene…
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have opened…
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers…
